Descrição
Cell proliferation assay results comparing melatonin-treated and control prostate cancer cells. MLT treatment appears to inhibit proliferation in both 22RV1 and C4-2 cell lines.
Figure 5
ChartSource Paper
Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.Cite This Figure
![Figure 5: Cell proliferation assay results comparing melatonin-treated and control prostate cancer cells. MLT treatment appears to inhibit proliferation in both 22RV1 and C4-2 cell lines.]() > Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)
<figure> <img src="" alt="Cell proliferation assay results comparing melatonin-treated and control prostate cancer cells. MLT treatment appears to inhibit proliferation in both 22RV1 and C4-2 cell lines." /> <figcaption>Figure 5. Cell proliferation assay results comparing melatonin-treated and control prostate cancer cells. MLT treatment appears to inhibit proliferation in both 22RV1 and C4-2 cell lines.<br> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption> </figure>